Learnin<div class="white-sheet">
<div class="wrapper mod3-home-slide module-header">
	<div class="nav">
		<button class="blue active arrow_box">MODULE 3</button>

		<button class="blue arrow_box show-overlay" data-effect="fade" data-duration="1000" data-target="learning-objectives-overlay" data-width="600" data-height="490">LEARNING OBJECTIVES</button>

		<button class="blue arrow_box navigate" data-navtarget="slide_sa_3">SELF-ASSESSMENT</button>

		<button class="blue arrow_box navigate" data-navtarget="slide_g_1_3">GLOSSARY</button>

		

		
	</div>

	<div class="module-title">
		<div class="title-1">Module 3</div>
		<div class="title-2">Composition and functions of the blood</div>
	</div>

	<button class="section-button but1 navigate" data-navtarget="slide_3_1">Section 3.1</button>
	<button class="section-button but2 navigate" data-navtarget="slide_3_2">Section 3.2</button>
	<button class="section-button but3 navigate" data-navtarget="slide_3_3">Section 3.3</button>
	<button class="section-button but4 navigate" data-navtarget="slide_3_4">Section 3.4</button>

	<!-- <button class="big-blue navigate" data-navtarget="slide_1_1">ENTER</button> -->

	<div class="gsk-logo"></div>

	<div class="learning-objectives-overlay overlay">

		<header>Learning Objectives</header>
			
		<ul>
			<li><span>By the end of this module you should be able to:</span>
				<ul>
					<li><span>Understand the details of the clinical trials and the outcomes relating to eltrombopag use in severe aplastic anaemia (SAA)</span>
						<ul>
							<li><span>Preclinical data in mice show that eltrombopag can stimulate multilineage haematopoiesis</span></li>
							<li><span>Phase II results demonstrate that eltrombopag can improve haematopoiesis in â‰¥1 cell lineage in patients with refractory aplastic anaemia</span>
								<ul>
									<li><span>A multilineage haematological response was observed in some patients, with an increase in platelet, red blood cell (RBC) and neutrophil levels after treatment with eltrombopag</span></li>
									<li><span>The number of cell lineages that met haematological response improved over time for some patients</span></li>
									<li><span>Response was maintained in patients whose treatment was tapered because of improvements in defined multilineage blood counts (platelets, erythrocytes and neutrophils)</span></li>
								</ul>
							</li>
						</ul>
					</li>
					<li><span>Appreciate that cytogenetic abnormalities and subsequent evolution to haematological malignancies are known long-term risks in patients with bone marrow disorders, particularly in patients with SAA</span>
						<ul>
							<li><span>Patients with aplastic anaemia are at risk for developing myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML)</span></li>
						</ul>
					</li>
				</ul>
			</li>
		</ul>

	</div>

</div>
</div>